FDA Approvals - Ranbaxy Receives FDA Approval to Market Simvastatin 80mg Tablets with
Ranbaxy Receives FDA Approval to Market Simvastatin 80mg Tablets with 180-Day Exclusivity (PR Newswire via Yahoo! Finance)
Ranbaxy Pharmaceuticals Inc. , a wholly owned subsidiary of Ranbaxy Laboratories Limited , announced today that the company has received approval from the U.S. Food and Drug Administration to manufacture and market Simvastatin Tablets USP, 80mg with 180-day exclusivity in the U.S.
Ranbaxy Receives FDA Approval to Market Simvastatin 80mg Tablets With 180-Day Exclusivity (RedNova)
PRINCETON, N.J., June 23 /PRNewswire/ -- Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced today that the company has received approval from the U.S.